Patents by Inventor Marla C. Dubinsky
Marla C. Dubinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230230697Abstract: Systems and methods are provided for evaluating a subject for inflammatory bowel disease (IBD) care coordination strategy. A resilience score is determined based on a plurality of different resilience domain assessments of the subject. When the resilience score satisfies a care coordination threshold, the subject is enlisted in an IBD care coordination program. An IBD severity score for the subject is determined based, at least in part, on one or more risk factors. Both the resilience score and the IBD severity score are used to assign the subject to a category in a plurality of categories. At least one time-limited care plan is determined at a first time for the subject based upon the identity of the assigned category. The at least one time-limited care plan is prioritized by an outcome of one or more resilience domain assessments in the plurality of different resilience domain assessments.Type: ApplicationFiled: May 26, 2021Publication date: July 20, 2023Inventors: Marla C. Dubinsky, Laurie Keefer
-
Publication number: 20220290235Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: ApplicationFiled: January 28, 2022Publication date: September 15, 2022Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Patent number: 11268149Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: GrantFiled: November 13, 2019Date of Patent: March 8, 2022Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Patent number: 11158428Abstract: A system and method for predicting medical outcomes of patients having a variety of diseases, and communicating these predicted outcomes to the patients. The system and method incorporates a plurality of variables and available medical treatments and/or therapies that are available to a patient. All of the variables and treatments are analyzed to predict medical outcomes without treatment, and with each of the plurality of available treatments. The system includes a graphical user interface for inputting the variables and the treatment options. This graphical user interface can comprise a plurality of toggle switches for manipulating each variable as desired. The graphical user interface can display a risk of complication of a disease, both with and without treatment, to a patient, thereby improving communication to the patient and providing healthcare providers and professionals with a procedure and system by which medical outcomes may be predicted and readily communicated to patient.Type: GrantFiled: January 5, 2015Date of Patent: October 26, 2021Assignee: MiTest Health LLCInventors: Corey A. Siegel, Lori S. Siegel, Marla C. Dubinsky
-
Publication number: 20200149110Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: ApplicationFiled: November 13, 2019Publication date: May 14, 2020Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Patent number: 10544459Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: GrantFiled: May 29, 2015Date of Patent: January 28, 2020Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20180142302Abstract: The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.Type: ApplicationFiled: January 11, 2018Publication date: May 24, 2018Inventors: Marla C. Dubinsky, Dermot P. McGovern, Jerome I. Rotter, Stephan R. Targan
-
Patent number: 9902996Abstract: The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.Type: GrantFiled: February 13, 2012Date of Patent: February 27, 2018Assignee: Cedars-Sinai Medical CenterInventors: Marla C. Dubinsky, Dermot P. McGovern, Jerome I. Rotter, Stephan R. Targan
-
Publication number: 20150376707Abstract: The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. These methods, kits and compositions may involve detecting risk/protective variants or haplotypes, serological markers, increased or decreased gene methylation, and increased or decreased cytokine secretion.Type: ApplicationFiled: September 8, 2015Publication date: December 31, 2015Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Stephan R. Targan, Jerome I. Rotter, Kent D. Taylor, Marla C. Dubinsky, Dermot P. McGovern, Talin Haritunians, Xiuqing Guo, Rebecca Gonsky, Richard Deem
-
Publication number: 20150259748Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: ApplicationFiled: May 29, 2015Publication date: September 17, 2015Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20140018447Abstract: The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD).Type: ApplicationFiled: March 26, 2012Publication date: January 16, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Dermot P. McGovern, Marla C. Dubinsky, Kent D. Taylor, Stephan R. Targan, Jerome I. Rotter
-
Publication number: 20120208900Abstract: The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.Type: ApplicationFiled: February 13, 2012Publication date: August 16, 2012Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Marla C. Dubinsky, Dermot P. McGovern, Jerome I. Rotter, Stephan R. Targan